key: cord-0844882-3cqrech5 authors: Dobaño, Carlota; Jiménez, Alfons; Rubio, Rocío; Alonso, Selena; Ramírez-Morros, Anna; Vidal, Marta; Vidal-Alaball, Josep; Ruiz-Comellas, Anna; García-Basteiro, Alberto L.; Izquierdo, Luis; Aguilar, Ruth; Moncunill, Gemma title: Spike-based COVID-19 immunization increases antibodies to nucleocapsid antigen date: 2021-10-25 journal: Transl Res DOI: 10.1016/j.trsl.2021.10.004 sha: 66e4b17c0803fcdcf008633d7bdb321a172bb554 doc_id: 844882 cord_uid: 3cqrech5 Antibodies to the nucleocapsid (N) antigen are suggested to be used to monitor infections after COVID-19 vaccination, as first generation subunit vaccines are based on the spike (S) protein. We used multiplex immunoassays to simultaneously measure antibody responses to different fragments of the SARS-CoV-2 S and N antigens for evaluating the immunogenicity of the mRNA-1273 (Spykevax) and the BNT162b2 (Comirnaty) vaccines in 445 health care workers. We report a >4-fold increase post-vaccination of IgG levels to the full length (N FL) and C-terminus of N (N CT) in 5.2% and 18.0% of individuals, respectively, and of IgA in 3.6% (N FL) and 9.0% (N CT) of them. The increase in IgG levels and avidity was more pronounced after Spykevax than Comirnaty vaccination (36.2% vs 13.1% for N CT, and 10.6% vs 3.7% for N FL). Data suggest the induction of cross-reactive antibodies against the N CT region after administering these S-based vaccines, and this should be taken into account when using N seropositivity to detect breakthroughs. We followed up a total of 445 health care workers (HCW, n=353 from hospital [6] terminal 6xHis-tag, transformed in E. coli BL21 DE3, induced with IPTG, and purified by affinity chromatography using HisTrap columns. The integrity of the proteins was checked by Coomassie 65 stained SDS-PAGE, showing >90% purity [9, 11] . The S antigens included a full length protein, as 66 well as its subregion S2, and the receptor-binding domain (RBD), as previously reported [10, 11] . Antigen-coupled microspheres were added to 384-well plates in multiplex and incubated with test 92 93 expected, we observed an unanticipated statistically significant increase in antibody responses to 96 N proteins, particularly against the N CT fragment ( Figure 1A ). The rise in antibody levels for each 97 antigen was consistent with an increase in percent seropositivity ( Table 1) . As expected, most 98 naïve subjects were seronegative for anti-N antibodies prior to vaccination. Specifically, levels of IgG and IgA, to the N CT fragment rose >4-fold in 18.06% and 9.0% of 100 vaccinated individuals, respectively (Table S1 ). This increase was not observed for IgM (data not 101 shown). Remarkably, the 4-fold increase in IgG was observed in more individuals for the Spykevax 102 (36.2%) than the Comirnaty (13.1%) vaccination (Tables 1, S1) and the increase in IgG reached 103 more statistical significance for the Moderna product (p<0.001) ( Figure 1A ). Examining the antibody responses to N FL, commonly used in serological evaluations, 5.2% and 105 3.6% of individuals had a >4-fold increase in IgG and IgA levels, respectively (Table S1 ), but the 106 patterns depended on the vaccine. Following COVID-19 Spykevax vaccination, levels of IgG and 107 IgA to N FL increased but to a lesser extent than to N CT ( Figure 1A) , with 10.6% of individuals 108 showing a >4-fold change in IgG levels (Table S1 ). In contrast, N FL IgG levels decreased pre-to Correlations were also significant but less strong when analyzing pre-vaccination antibody levels: We performed additional experiments to understand the observed raise in antibodies to an antigen 118 (N) that is not included in the vaccine. We first discarded non-specific effects of the mRNA COVID-119 19 vaccines, or bystander activity, since antibody responses to other vaccine antigens (hepatitis B 120 virus, diphtheria, tetanus, pertussis) or to N from common cold human coronaviruses did not 121 significantly increase; in fact, some of them decreased after vaccination like N FL (data not shown). We also discarded that this antibody increase was due to multispecific or polyreactive 123 memory T helper or B cells in SARS-CoV-2 pre-exposed individuals, whereby a booster response 124 against S through vaccination would also recall responses against non-vaccine antigens in the 125 virus (N), since this phenomenon was also observed in naïve volunteers. The finding that pre-126 exposed individuals had a stronger increase in N CT IgG levels after vaccination mirrors the 127 booster effect that is seen with S ( Figure 1A ). Since correlation analyses suggested that antibodies induced by both mRNA vaccines could be 129 due to cross-reactivity between N and S epitopes, we aligned the primary amino acid sequences of Although these alignments did not provide strong evidence for cross-reactivity, at least at the linear 135 epitope level, we also tested other fragments of the N protein to try mapping the target epitopes. Finally, testing the avidity of antibodies following vaccination, we found that cross-reactive 141 antibodies did not bind weakly to N ( Figure 1B) . Thus, the increase in anti-N antibody levels pre-to We report an increase in IgG and IgA to the N protein, specifically to the N CT, early after COVID-149 19 vaccination, with a more pronounced IgG rise for the Spykevax than the Comirnaty vaccine. These results suggest the presence of cross-reactive antibodies against the C-terminal region of the SARS-CoV-2 N protein after vaccination with S-based mRNA vaccines. Avidity assays indicate 152 that the binding of vaccine-induced cross-reactive antibodies to N CT epitopes is not mediated by 153 weak interactions that are characteristic of non-specific or polyreactive antibodies. We hypothesize 154 that the amino acid residues recognized by these antibodies are either constituted by 155 conformational epitopes [13], or very short amino acid stretches not captured by sequence 156 alignment, possibly located between amino acids 340-416 of N, considering that B cell epitopes 157 can be as short as 4-5 amino acids in length. A lack of antibody response against N FL after vaccination with mRNA vaccines has been 159 previously reported [5, 12] , and the decay we observe is consistent with a gradual waning of N 160 antibodies with time. In kinetics studies, antibodies to N FL tend to decrease more markedly and 161 rapidly with time post-infection compared to S antibodies. Therefore, the pattern found here could 162 reflect the dynamics of the IgG response to N FL after infection with SARS-CoV-2 (in exposed) and/or to common cold human coronaviruses (in naive), which keep decreasing from pre to post 164 vaccination. Besides the natural antibody decay, the decrease in IgG to N FL upon vaccination 165 could be related to a redirection of antibody production to vaccine specific immunogens in 166 detriment of other targets. Finally, it is highly unlikely that the increase in IgG and IgA levels against N post-vaccination is due 168 to asymptomatic infections given the high proportion of antibody increasers. Moreover, upon recent 169 infection, the magnitude of the increase in N FL antibodies would be much bigger particularly in 170 previously exposed individuals, thus this option was also discarded. Our results have significant public health relevance because the N protein is being suggested to Efficacy and Safety of 223 the mRNA-1273 SARS-CoV-2 Vaccine Delta variant 226 and mRNA Covid-19 vaccines effectiveness: higher odds of vaccine infection 227 breakthroughs Viral targets for vaccines against COVID-19 Comparative 232 Assessment of Sera from Individuals after S-Gene RNA-Based SARS-CoV-2 Vaccination 233 with Spike-Protein-Based and Nucleocapsid-Based Serological Assays Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large 239 Spanish reference hospital Persistence and baseline determinants of seropositivity and reinfection rates in health care 243 workers up to 12.5 months after COVID-19 Safety and 246 Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Immunogenicity 249 and crossreactivity of antibodies to the nucleocapsid protein of SARS-CoV-2: utility and 250 limitations in seroprevalence and immunity studies A 253 serological assay to detect SARS-CoV-2 seroconversion in humans Highly sensitive and 256 specific multiplex antibody assays to quantify immunoglobulins M CoV-2 antigens Antibody 260 Responses after a Single Dose of SARS-CoV-2 mRNA Vaccine Cross-React: a new structural bioinformatics method for predicting 263 allergen cross-reactivity Comparison of SARS-CoV-2 266 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273 COVID-19 Vaccine Breakthrough Case Investigation and Reporting. CDC; COVID 269 Vaccination Evaluation of COVID-19 vaccine effectiveness: interim guidance World Heal Organ 2021:viii Unbiased interrogation of memory B cells from convalescent COVID-19 patients reveals a 274 broad antiviral humoral response targeting SARS-CoV-2 antigens beyond the spike protein